Skip to Content

News Releases

Sep 26 2022
SomaLogic's Chief Medical Officer Steve Williams honored with C-Suite Award by the Denver Business Journal
BOULDER, Colo., Sept. 26, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced that Chief Medical Officer Steve Williams, M.D., Ph.D., has been named a 2022 C-Suite Award winner by the Denver Business Journal.
Sep 14 2022
SomaLogic to Present at the Capital One Spatial Biology & Proteomics Summit
BOULDER, Colo., Sept. 14, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that management will be participating in the upcoming Capital One Spatial Biology & Proteomics Summit taking place virtually on Wednesday, September 28.
Aug 31 2022
SomaLogic to Present at Morgan Stanley 20th Annual Global Healthcare Conference
BOULDER, Colo., Aug. 31, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference in New York, New York.
Aug 15 2022
SomaLogic Reports Second Quarter 2022 Financial Results
Second quarter 2022 revenue of $14.1 million, bringing year to date revenue to $37.1 million. Reducing 2022 revenue guidance to $80-90 million to account for ongoing variability in core service business, macroeconomic and commercial factors. Maintaining substantial cash, cash equivalents, and
Jul 26 2022
SomaLogic acquires DNA nanotechnology leader Palamedrix to develop the next-generation SomaScan® Assay
Brings differentiated miniaturization technology, scientific and engineering expertise, and enhanced ease-of-use capabilities to SomaLogic’s platform while expanding footprint to San Diego, CA BOULDER, Colo. and SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI
Jul 25 2022
SomaLogic to Announce Second Quarter 2022 Financial Results
BOULDER, Colo. , July 25, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the second quarter 2022 after market close on Monday, August 15, 2022. Company management will host a corresponding audio
Jun 13 2022
SomaLogic Announces License Agreement with OncoHost for the Development of Precision Cancer Diagnostics
BOULDER, Colo. and BINYAMINA, Israel, June 13, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced it has signed a licensing agreement with OncoHost, a global leader in next-generation precision oncology for personalized cancer therapy.
Jun 01 2022
SomaLogic Announces June Conference Participation
BOULDER, Colo., June 01, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the following conferences. Jefferies Healthcare Conference June 8-9, 2022, in New York 7th Annual MarketsandMarkets
May 12 2022
SomaLogic Reports First Quarter 2022 Financial Results
Company to host conference call today at 4:30 p.m. ET BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended March 31, 2022. “Our successful first quarter has kickstarted another
Apr 21 2022
SomaLogic to Announce First Quarter 2022 Financial Results
BOULDER, Colo., April 21, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the first quarter 2022 after market close on Thursday, May 12, 2022. Company management will host a corresponding
Displaying 1 - 10 of 22